The IASLC WCLC meeting, held in Barcelona this year, covered many interesting topics and reported data from clinical trials relevant to the management of lung cancer. In the… read more.
Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.
Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.
WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.
Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.
Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.
The ALK- and ROS1-inhibitor brigatinib showed a better progression-free survival (PFS) compared to the ALK-inhibitor crizotinib in the first interim analysis of a head-to-head trial in patients with… read more.
Professor Gail Darling (WCLC co-President, Toronto, Canada) discusses the success of combined screening and smoking cessation pilot in Ontario.
Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) and Professor David Baldwin (Nottingham, UK) detail current UK pilots and a screening protocol that is currently going through the NHS England… read more.
A randomised, controlled screening trial for lung cancer involving almost 16,000 people in the Netherlands and Belgium found that CT screening produced a 26% reduction in lung cancer… read more.
The IASLC 19th World Conference on Lung Cancer (WCLC) was full of highlights, including 3 plenary abstracts being presented in the New England Journal of Medicine and involvement from… read more.
by Marybeth Burke – Afatinib, an irreversible ErbB-family blocker, delays progression of advanced lung cancer in patients with epidermal growth factor receptor (EGFR) mutations compared with standard chemotherapy,